ARIO PHARMA
Ario Pharma ltd focusses on the development of drugs for the treatment of respiratory indications. Ario is about to evaluate the anti-tussive properties of XEN-D0501, a potential best-in-class TRPV1 inhibitor, in two Phase 2 clinical trials that will read out in 2014. The company is managed by a highly experienced development team and supported by world-renowned KOLs in respiratory disease.
ARIO PHARMA
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2010-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.ariopharma.com
Total Employee:
1+
Status:
Active
Contact:
(+44) 1223 493922
Total Funding:
3.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Amazon Organization Schema
Current Employees Featured
Founder
Investors List
New Science Ventures
New Science Ventures investment in Seed Round - Ario Pharma
Forbion Capital Partners
Forbion Capital Partners investment in Seed Round - Ario Pharma
Official Site Inspections
http://www.ariopharma.com
- Host name: ec2-3-130-253-23.us-east-2.compute.amazonaws.com
- IP address: 3.130.253.23
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
